文献速递临床试验与 GCP

Lorundrostat 用于未控制高血压及难治性高血压受试者:Launch-HTN 随机临床试验

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项 3 期随机临床试验在 13 个国家 159 个中心纳入 1083 例未控制高血压(含难治性高血压)成人,比较 lorundrostat 50 mg/d(合并 50→100 mg/d 组)与安慰剂。第 6 周诊室收缩压最小二乘均值变化:合并 50 mg 组 -16.9 mm Hg,安慰剂组 -7.9 mm Hg,差值 -9.1 mm Hg(95%CI -13.3 至 -4.9,P<.001)。低钠血症、高钾血症和肾功能下降在 lorundrostat 组更常见。

要点

  • 第 6 周收缩压降幅:合并 50 mg lorundrostat 组 -16.9 mm Hg,安慰剂组 -7.9 mm Hg,差值 -9.1 mm Hg。
  • 低钠血症、高钾血症和肾功能下降在 lorundrostat 组较安慰剂组更常见。
  • 50 mg 组因高钾血症停药 2 例(0.37%)、低钠血症 2 例(0.37%)、肾功能下降 3 例(0.56%)。

核心结论

  • 作者结论认为,醛固酮合酶抑制剂 lorundrostat 在未控制高血压(含难治性高血压)成人中降低血压的有效性和安全性得到证实。

研究设计与样本

  • 3 期随机临床试验,2023 年 11 月至 2024 年 9 月在 13 个国家 159 个中心入组未控制高血压(含难治性高血压)成人,末次随访日期为 2025 年 1 月 24 日。
  • 按 1:2:1 随机分为 50 mg/d lorundrostat 6 周后符合预设标准者升至 100 mg/d 再用 6 周(n=270)、50 mg/d lorundrostat 12 周(n=541)、安慰剂 12 周(n=272)。
  • 预设升量标准包括收缩压≥130 mm Hg、钾≤4.8 mmol/L、钠≥135 mmol/L、eGFR>45 mL/min/1.73 m2 且 eGFR 下降<25%。
  • 共 1083 例参与者,平均年龄 61.6 岁(SD 10.3),女性 508 例(46.9%),黑人/非裔美国人 311 例(28.7%),白人 733 例(67.7%),BMI≥30 者 685 例(63.3%)。
  • 随机时服用 2 种降压药者 432 例(39.9%),服用 3 种及以上者 651 例(60.1%)。

主要发现

  • 主要结局为第 6 周自动诊室收缩压变化,合并 50 mg lorundrostat 组(n=808)最小二乘均值变化 -16.9 mm Hg(95%CI -19.0 至 -14.9),安慰剂组 -7.9 mm Hg(95%CI -11.5 至 -4.2),最小二乘均值差 -9.1 mm Hg(95%CI -13.3 至 -4.9;P<.001)。
  • 低钠血症、高钾血症和肾功能下降在 lorundrostat 组较安慰剂组报告更频繁。
  • 50 mg 组可升至 100 mg 者中,因高钾血症停药 1 例(0.37%)、低钠血症 1 例(0.37%)、肾功能下降 0 例。
  • 50 mg 组中因高钾血症停药 2 例(0.37%)、低钠血症 2 例(0.37%)、肾功能下降 3 例(0.56%)。
  • 治疗中出现的不良事件发生于 49.9% 的参与者(538/1078),严重程度多为轻或中度。

关键数值与推荐

  • 主要结局比较第 6 周合并 50 mg lorundrostat 组与安慰剂组的自动诊室收缩压变化。
  • 特别关注的不良事件包括因高钾血症、低钠血症和肾功能下降导致的减量、中断或停药。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Uncontrolled hypertension remains a global health concern and dysregulated aldosterone production is a central mechanism. Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone production, demonstrated efficacy in participants with uncontrolled hypertension, including those with treatment-resistant hypertension. OBJECTIVE: To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension. DESIGN, SETTING, AND PARTICIPANTS: In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025. INTERVENTION: Randomization ratio of 1:2:1 to 50 mg/d of lorundrostat for 6 weeks followed by 100 mg/d of lorundrostat for 6 weeks (n = 270) if they met prespecified criteria, 50 mg/d of lorundrostat for 12 weeks (n = 541), or daily placebo for 12 weeks (n = 272). The prespecified criteria included systolic BP of 130 mm Hg or greater, potassium level of 4.8 mmol/L or less, sodium level of 135 mmol/L or greater, an estimated glomerular filtration rate (eGFR) of greater than 45 mL/min/1.73 m2, and less than a 25% reduction in eGFR. MAIN OUTCOME AND MEASURES: The primary outcome was change in automated office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. Adverse events of special interest included dose reduction, interruption, or discontinuation due to events such as hyperkalemia, hyponatremia, and reduction in kidney function. RESULTS: Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more. For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was -16.9 mm Hg (95% CI, -19.0 to -14.9 mm Hg) vs -7.9 mm Hg (95% CI, -11.5 to -4.2 mm Hg) for the placebo group (least-squares mean difference, -9.1 mm Hg [95% CI, -13.3 to -4.9 mm Hg]; P < .001). Hyponatremia, hyperkalemia, and reduction in kidney function were reported more often with lorundrostat vs placebo. In the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 participant (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function. In the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 participants (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function. Treatment-emergent adverse events occurred in 49.9% of participants (538/1078) and were mostly mild or moderate in severity. CONCLUSIONS AND RELEVANCE: The efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, was demonstrated for lowering BP in adults with uncontrolled hypertension, including those with treatment-resistant hypertension. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06153693.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025. PMID: 40587141. doi:10.1001/jama.2025.9413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。